Department of Gene Therapy, Faculty of Medicine, Nicolaus Copernicus University, Skłodowskiej-Curie 9, 85-094 Bydgoszcz, Poland.
Arch Immunol Ther Exp (Warsz). 2010 Dec;58(6):417-25. doi: 10.1007/s00005-010-0098-6. Epub 2010 Sep 26.
Interleukin (IL)-27 is a novel cytokine secreted by stimulated antigen-presenting cells. Initial studies on the biology of IL-27 provided evidence for its role in the initiation of T(H)1 responses; however, subsequent work has indicated that IL-27 has broad inhibitory effects on T(H)1, T(H)2, and T(H)17 subsets of T cells as well as the expansion of inducible regulatory T cells. The involvement of IL-27 in the regulation of angiogenesis and antiviral response has also recently been reported. The aim of this review is to highlight the potential areas of IL-27 clinical application, especially the management of neoplastic and viral diseases as well as autoimmune disorders, including rheumatoid arthritis and multiple sclerosis. The review will also serve to elaborate on the molecular mechanisms involved in the expression of this cytokine and signaling from the IL-27 receptor.
白细胞介素 (IL)-27 是一种由受刺激的抗原呈递细胞分泌的新型细胞因子。最初对 IL-27 生物学的研究为其在 T(H)1 反应的启动中的作用提供了证据;然而,随后的工作表明,IL-27 对 T(H)1、T(H)2 和 T(H)17 亚群的 T 细胞以及诱导性调节性 T 细胞的扩增具有广泛的抑制作用。IL-27 参与血管生成和抗病毒反应的调节也最近被报道。本文综述的目的是强调 IL-27 临床应用的潜在领域,特别是在治疗肿瘤和病毒性疾病以及自身免疫性疾病,包括类风湿关节炎和多发性硬化症中的应用。该综述还将详细阐述该细胞因子表达和 IL-27 受体信号转导所涉及的分子机制。